Raw Materials in Focus: Enabling Platform-Based ATMP Development​

This editorial examines how variability in raw materials—particularly human serum albumin (HSA)—undermines reproducibility and can jeopardise facilitated or expedited approval pathways. As cell therapy developers expand platform approaches to multiple diseases, including rare conditions with small patient populations, manufacturing consistency becomes non‑negotiable. It makes the case for animal-origin free, high‑quality recombinant alternatives such as Recombumin^® to drive consistency and de‑risk development. 

Read how raw material consistency is enabling platform‑ready advanced therapies.